CCAIM

Artificial Intelligence and machine learning have the potential to solve some of the most intractable problems in biomedical science, turbocharge medical discovery and, critically, revolutionise healthcare delivery.

The Cambridge Centre for AI in Medicine, is helping to make this a reality through its world-leading research, close partnerships with the NHS and industry, and a range of upcoming education initiatives. To reach this goal, our partners at AstraZeneca, Boehringer Ingelheim, GSK, McKinsey & Company QuantumBlack, Sanofi and Takeda, not only provide funding but also strategic input for the issues important in drug development and patient care.

The Centre’s overarching aim is a breakthrough in the understanding and treatment of complex diseases, with the more immediate goals of transforming personalised healthcare delivery – including the effective administration of treatments over time – and pioneering, next-generation clinical trials.

We will fulfill these goals using approaches including novel algorithms, methods and systems for biomedical discovery, omics analytics, precision medicine – including early diagnostics – and next-generation adaptive clinical trials.  

Successfully bridging the gap between the complex fields of AI, bioscience and medicine requires deep interdisciplinary collaboration. That is why CCAIM comprises a unique coalition of leading Cambridge scientists, clinicians, medical researchers, geneticists, computational biologists and biostatisticians. The centre’s expertise is broad and deep.